Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Clonal hematopoiesis in the cancer setting

Rafael Bejar • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes

Rafael Bejar, MD, PhD, UC San Diego Moores Cancer Center, San Diego, CA, discusses the clinical implications of clonal hematopoiesis in the cancer setting. Specifically, he focuses on therapy-related myeloid neoplasms and potential strategies to counter clonal expansion. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Rafael Bejar

CHIP and implications for myeloproliferative neoplasms
Rafael Bejar • 10 Nov 2022
1:53
The role of chronic inflammation in clonal hematopoiesis and the development of MDS
Rafael Bejar • 26 Aug 2022
1:32
The role of the innate immune system in MDS pathogenesis
Rafael Bejar • 26 Aug 2022
1:45
The importance of genomic testing in MPNs and other myeloid malignancies
Rafael Bejar • 26 Aug 2022

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals